IDEXX Laboratories, Inc. (ETR:IX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 37.14B -18.1% |
| Revenue (ttm) | 3.99B +12.8% |
| Net Income | 997.54M +15.6% |
| EPS | 12.45 +18.4% |
| Shares Out | n/a |
| PE Ratio | 37.23 |
| Forward PE | 34.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13 |
| Open | 480.40 |
| Previous Close | 482.70 |
| Day's Range | 480.40 - 480.40 |
| 52-Week Range | 448.00 - 663.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial numbers in USD Financial StatementsNews
IDEXX Laboratories Transcript: Investor Day 2026
A multi-decade innovation cycle is driving new diagnostic platforms, menu expansion, and AI-powered software, supporting double-digit recurring revenue growth and high margins. Sector tailwinds include aging pets, breed shifts, and rising preventive care. Guidance targets 8.5%-11% recurring revenue growth and >32% operating margins.
IDEXX Laboratories Slides: FY 2026
IDEXX Laboratories has posted slides in relation to its FY 2026 quarterly earnings report, which was published on August 13, 2026.
Idexx Laboratories announces launch of Catalyst proBNP Test
IDEXX Laboratories (IDXX) announced the launch of the Catalyst proBNP Test, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a bi...
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.
Idexx Laboratories price target lowered to $710 from $800 at Barclays
Barclays analyst Glen Santangelo lowered the firm’s price target on Idexx Laboratories (IDXX) to $710 from $800 and keeps an Overweight rating on the shares. The company reported a strong…
Idexx Laboratories price target raised to $670 from $620 at UBS
UBS analyst Andrea Alfonso raised the firm’s price target on Idexx Laboratories (IDXX) to $670 from $620 and keeps a Neutral rating on the shares.
Idexx Laboratories price target raised to $670 from $650 at Citi
Citi analyst Daniel Grosslight raised the firm’s price target on Idexx Laboratories (IDXX) to $670 from $650 and keeps a Neutral rating on the shares.
Idexx Laboratories reports Q2 EPS $4.27, consensus $3.93
Reports Q2 revenue $1.22B, consensus $1.2B. “Our Q2 results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx…
IDEXX Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 delivered 10% revenue growth and 18% EPS growth, driven by strong CAG Diagnostics, international expansion, and innovation adoption. Full-year guidance was raised for revenue, EPS, and free cash flow conversion, with continued investments in R&D and commercial capabilities.
IDEXX Laboratories Earnings release: Q2 2026
IDEXX Laboratories released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
IDEXX Laboratories Slides: Q2 2026
IDEXX Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
IDEXX Laboratories Quarterly report: Q2 2026
IDEXX Laboratories has published its Q2 2026 quarterly earnings report on August 4, 2026.
Idexx Laboratories raises FY26 EPS view to $14.69-$14.94 from $14.45-$14.90
2026 EPS consensus $14.66. Narrows 2026 revenue view to $4.70B-$4.745B from $4.675B-$4.760B, consensus $4.71B.
IDEXX Laboratories Announces Second Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company rep...
IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.
Idexx Laboratories price target lowered to $620 from $640 at UBS
UBS lowered the firm’s price target on Idexx Laboratories (IDXX) to $620 from $640 and keeps a Neutral rating on the shares.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tue...
IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2026
The new CEO is driving a purpose-led strategy focused on innovation, global expansion, and integrated diagnostics and software. AI and new platforms like inVue Dx and Cancer Dx are fueling growth, with strong adoption and expanding capabilities. The company expects continued momentum from a robust pipeline and sector tailwinds.
Idexx Laboratories expands Fecal Dx platform for taeniid tapeworm detection
IDEXX Laboratories (IDXX) announced the expansion of its Fecal Dx antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intest...
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
Idexx Laboratories announces SDMA to be built into Catalyst CLIPs
IDEXX Laboratories (IDXX) announced that SDMA, a renal biomarker, will be built into Catalyst CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles...
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, wil...
IDEXX Laboratories Transcript: AGM 2026
The meeting featured a CEO transition, approval of all management proposals including board declassification and special meeting rights for 25% shareholders, and rejection of a shareholder proposal for a 10% threshold. No questions were raised during the Q&A.
Idexx Laboratories price target lowered to $660 from $790 at BofA
BofA lowered the firm’s price target on Idexx Laboratories (IDXX) to $660 from $790 and keeps a Neutral rating on the shares. The firm sees today’s Q1 beat as “demonstrating…